ANGIOSARCOMAS TREATMENT MARKET ANALYSIS

Angiosarcoma is a rare cancer of the inner lining of blood vessels, which occur in any area of the body, including the skin, breast, liver, spleen, and deep tissue and originates due to the transformation of mesenchymal cells. Angiosarcoma is known to appear on skin of face, while growth of these tumors increases the risk of mortality. The treatment options available for angiosarcoma include surgery, chemotherapy, and radiotherapy. Though the disease is rare, its severity and ability to spread, are expected to major factors increasing growth of the angiosarcoma treatment market over the forecast period.

Various types of angiosarcoma include Epithelioid Angiosarcoma, Cardiac Angiosarcoma, Hepatic Angiosarcoma, and Cutaneous Angiosarcoma. As per the stats of Know Cancer—an institute known for connecting cancer infected people to empower and educate them about cancer—cutaneous angiosarcoma contributes to the maximum of angiosarcoma cases, which is around 60% followed by angiosarcoma found in deep tissue and in breast tissue contributes around 35% of overall cases. Symptoms associated with angiosarcoma include skin lesions, bone pain, fatigue, anemia, and heart pain, though these vary according to the location of the angiosarcoma.

According to the National Cancer Institute (NCI), around 50% of the people suffering from angiosarcoma, have a survival rate of around 5 year from onset. Those who respond to treatment and show some recovery in first 5 years after diagnosis of angiosarcoma, have higher chances of survival, than those that are not diagnosed on time. According to the data published by NCI in 2014, based on a 5-year study, the survival rate for sarcoma was pegged at 90% at the first stage, 81% at the second stage, 56% during the third stage, while survival during the fourth stage is highly unlikely. Diagnostics tests such as CT, PET, MRI scan, and biopsy tests are widely used for the effective diagnosis of angiosarcoma.

As per results of a study by Coherent Market Insights, in August 2015, the incidence rate for this disease is low, with angiosarcoma contributing to 1-2% towards sarcoma cases. Rising number of cancer cases inadvertently is expected to create a highly conducive environment for growth of the angiosarcoma treatment market.

As per stats published by the European Medicines Agency in January 2017, around 3.5 in 10,000 people were affected by angiosarcoma in Europe, in 2016. While in the U.S., angiosarcoma accounted for only 0.7% of cancer cases, making it a rare type of cancer.

Angiosarcomas Treatment Market Taxonomy:

By Location of Instigation

• Hemangiosarcoma
• Lymphangiosarcoma

By Type of Treatment

• Surgery
• Chemotherapy
• Radiotherapy

Rising prevalence of angiosarcoma disease and increasing research and development to boost market growth

The market in North America accounts for the dominant market globally, as major research and development activities are carried out in this region. North America thus, accounts for the largest market share, followed by Europe, which is backed up by growing healthcare infrastructure, availability of affordability of drugs, and high awareness about available treatments in the region..

As the disease is rare, a few organizations are investing in research and development, which in turn increases the cost of drugs, posing as major factors restraining growth of the angiosarcoma treatment market. However, considering the projected increase in incidence of the disease in the near future, the market is expected to witness the entry of various new players.

Major companies involved in the angiosarcoma treatment market include Genentech, Inc., Pfizer Inc., Janssen Global Services, LLC, Bayer AG, Sanofi, and Amgen Inc.